This is a match-making section for JPIAMR 14th call - Disrupting drug Resistance Using Innovative Design (DRUID).
Human Health
in silico, in vitro, in vivo
radiotracers diagnosis radionuclide therapy affibodyUsing radioisotopes
Radioisotope production and developing radiopharmaceuticals fot PET imaging and for the targeted radionuclide therapy by alpha and Auger electron particles. We have radiochemical lab with cylotron, aseptic lab for production radiopharmaceuticals, cell labor, miniPET camera for pre-clinical animal study too.
We believe that the new generation of group of metal radioactive ion in chelat bond, conjugated to the high specific vector molecule such as affibody will be a general poverful tool against tumors ans their metastates, as well as against some heavy diseas as multiresistant TB, HIV etc.
Submitted on 2022-06-01 11:31:37
« Return to the partner search tool